ImmunoGen, Inc. (NASDAQ: IMGN) today announced that Blaine McKee, Ph.D. has been appointed Executive Vice President and Chief Business Officer.“As ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Management Changes Management Comments

Immunogen (IMGN) Reports Successful Completion of Interim Analysis for FORWARD I Phase 3 Trial of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian CancerApril 26, 2018 4:38 PM ImmunoGen Appoints Blaine McKee as Executive Vice President and Chief Business OfficerApril 25, 2018 8:00 AM